[go: up one dir, main page]

NL174943C - Werkwijze ter bereiding van farmaceutische preparaten en werkwijze ter bereiding van een 8-azapurin-6-onderivaat. - Google Patents

Werkwijze ter bereiding van farmaceutische preparaten en werkwijze ter bereiding van een 8-azapurin-6-onderivaat.

Info

Publication number
NL174943C
NL174943C NLAANVRAGE7117142,A NL7117142A NL174943C NL 174943 C NL174943 C NL 174943C NL 7117142 A NL7117142 A NL 7117142A NL 174943 C NL174943 C NL 174943C
Authority
NL
Netherlands
Prior art keywords
preparing
azapurin
derivative
sub
pharmaceutical preparations
Prior art date
Application number
NLAANVRAGE7117142,A
Other languages
English (en)
Dutch (nl)
Other versions
NL174943B (nl
NL7117142A (de
Original Assignee
May & Baker Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by May & Baker Ltd filed Critical May & Baker Ltd
Publication of NL7117142A publication Critical patent/NL7117142A/xx
Publication of NL174943B publication Critical patent/NL174943B/xx
Application granted granted Critical
Publication of NL174943C publication Critical patent/NL174943C/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NLAANVRAGE7117142,A 1970-12-15 1971-12-14 Werkwijze ter bereiding van farmaceutische preparaten en werkwijze ter bereiding van een 8-azapurin-6-onderivaat. NL174943C (nl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB5955270 1970-12-15
GB5955670 1970-12-15
GB4975671A GB1338235A (en) 1970-12-15 1971-10-26 Azapurinones
GB5345771 1971-11-17

Publications (3)

Publication Number Publication Date
NL7117142A NL7117142A (de) 1972-06-19
NL174943B NL174943B (nl) 1984-04-02
NL174943C true NL174943C (nl) 1984-09-03

Family

ID=27449009

Family Applications (1)

Application Number Title Priority Date Filing Date
NLAANVRAGE7117142,A NL174943C (nl) 1970-12-15 1971-12-14 Werkwijze ter bereiding van farmaceutische preparaten en werkwijze ter bereiding van een 8-azapurin-6-onderivaat.

Country Status (25)

Country Link
US (1) US3987160A (de)
JP (1) JPS5310599B1 (de)
AR (4) AR192602A1 (de)
AT (4) AT317211B (de)
AU (1) AU458277B2 (de)
BE (1) BE776683A (de)
BG (3) BG20805A3 (de)
CH (5) CH556860A (de)
DD (1) DD95007A5 (de)
DE (1) DE2162096A1 (de)
DK (1) DK141249B (de)
FI (1) FI53457C (de)
FR (1) FR2118078B1 (de)
GB (1) GB1338235A (de)
HK (1) HK42177A (de)
HU (1) HU165079B (de)
IE (1) IE35897B1 (de)
IL (1) IL38364A (de)
IS (1) IS1099B6 (de)
LU (1) LU64457A1 (de)
NL (1) NL174943C (de)
NO (1) NO134257C (de)
OA (1) OA03930A (de)
SE (1) SE393381B (de)
ZM (1) ZM18971A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1493685A (en) * 1970-12-15 1977-11-30 May & Baker Ltd 8-azapurinones
BE792648A (fr) * 1971-12-13 1973-06-12 May & Baker Ltd Derives de l'isoquinoleine
FR2406638A1 (fr) * 1977-10-21 1979-05-18 May & Baker Ltd Nouvelles aza-8 purinones-6, leur preparation et les compositions pharmaceutiques les contenant
EP0007727B1 (de) * 1978-07-24 1983-11-30 Beecham Group Plc Benzopyranotriazole, Verfahren zur Herstellung dieser Verbindungen und diese enthaltende pharmazeutische Zusammensetzung
JPS60226887A (ja) * 1984-04-25 1985-11-12 Dai Ichi Seiyaku Co Ltd トリアゾロピリミジン誘導体
CA1303037C (en) * 1987-02-02 1992-06-09 Smith Kline & French Laboratories Limited Purinone derivatives as bronchodilators vasodilators and anti-allergic agents
DE3873812D1 (de) * 1987-04-07 1992-09-24 Ciba Geigy Ag 3h-1,2,3-triazolo(4,5-d)pyrimidine.
US5204353A (en) * 1987-04-07 1993-04-20 Ciba-Geigy Corporation 3-benzyl-3H-1,2,3-triazolo[4,5-d]pyrimidines, compositions thereof, and method of treating epilepsy therewith
FR2618073B1 (fr) * 1987-07-16 1990-09-07 Pf Medicament Comprimes de type a matrice hydrophile a base de salbutamol et leur procede de preparation
GB8817651D0 (en) * 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
DE4211239C2 (de) * 1992-04-03 1995-11-16 Max Planck Gesellschaft Arzneimittel gegen Herz-Kreislauf-Erkrankungen
GB9213623D0 (en) * 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents
US5734053A (en) * 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US20080045573A1 (en) * 1993-09-20 2008-02-21 Bova David J Methods and Sustained Release Nicotinic Acid Compositions for Treating Hyperlipidemia
US6080428A (en) * 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6129930A (en) * 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
GB9404485D0 (en) * 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
EP2295436A1 (de) 1997-11-12 2011-03-16 Bayer Schering Pharma AG 2-Phenyl-substituierte Imidazotriazinone als Phosphodiesterase V Inhibitoren
DE19838705A1 (de) 1998-08-26 2000-03-02 Bayer Ag Neue Dihydro-(1,2,3)-triazolo-[4,5-d]pyrimidin-7-one
IT1318674B1 (it) * 2000-08-08 2003-08-27 Nicox Sa Faramaci per l'incontinenza.
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MX357121B (es) 2011-03-01 2018-06-27 Synergy Pharmaceuticals Inc Star Proceso de preparacion de agonistas c de guanilato ciclasa.
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
EP3004138B1 (de) 2013-06-05 2024-03-13 Bausch Health Ireland Limited Ultrareine agonisten von guanylatcyclase c, verfahren zur herstellung und verwendung davon
JP6694385B2 (ja) 2013-08-09 2020-05-13 アーデリクス，インコーポレーテッド リン酸塩輸送阻害のための化合物及び方法
CN110381951A (zh) 2016-12-14 2019-10-25 瑞必治公司 用于治疗肺性高血压和其他肺病症的方法及组合物
TWI845600B (zh) 2019-01-24 2024-06-21 美商普羅米修斯生物科學股份有限公司 Gpr35調節劑
US20200368223A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Methods for inhibiting phosphate transport
EP4185379A4 (de) * 2020-07-23 2023-11-22 Prometheus Biosciences, Inc. Gegen gpr35 gerichtete therapeutika

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2407204A (en) * 1944-07-22 1946-09-03 American Cyanamid Co Triazolo (d) pyrimidines and methods of preparing the same
US2993039A (en) * 1959-11-06 1961-07-18 Upjohn Co Preparing nu-glycosides of aldose and ketose sugars

Also Published As

Publication number Publication date
AT317211B (de) 1974-08-26
US3987160A (en) 1976-10-19
AR192602A1 (es) 1973-02-28
HK42177A (en) 1977-08-19
JPS5310599B1 (de) 1978-04-14
DK141249C (de) 1980-08-04
CH556860A (de) 1974-12-13
CH546779A (fr) 1974-03-15
CH555351A (fr) 1974-10-31
GB1338235A (en) 1973-11-21
CH550814A (fr) 1974-06-28
FR2118078A1 (de) 1972-07-28
IE35897B1 (en) 1976-06-23
AR199467A1 (es) 1974-09-09
IS1099B6 (is) 1982-11-18
AT319235B (de) 1974-12-10
BG20805A3 (bg) 1975-12-20
DK141249B (da) 1980-02-11
IE35897L (en) 1972-06-15
FI53457C (fi) 1978-05-10
HU165079B (de) 1974-06-28
BG20807A3 (bg) 1975-12-20
AT315838B (de) 1974-06-10
AT315839B (de) 1974-06-10
LU64457A1 (de) 1972-08-23
BG20806A3 (bg) 1975-12-20
NL174943B (nl) 1984-04-02
FI53457B (de) 1978-01-31
AU3686771A (en) 1973-06-21
NL7117142A (de) 1972-06-19
DE2162096C2 (de) 1988-02-11
OA03930A (fr) 1975-08-14
IL38364A0 (en) 1972-02-29
FR2118078B1 (de) 1975-08-01
IL38364A (en) 1975-08-31
ZM18971A1 (en) 1972-08-21
AR192689A1 (es) 1973-02-28
AU458277B2 (en) 1975-02-20
DE2162096A1 (de) 1972-07-06
IS2047A7 (is) 1972-06-16
BE776683A (fr) 1972-06-14
CH552610A (fr) 1974-08-15
AR199468A1 (es) 1974-09-09
SE393381B (sv) 1977-05-09
NO134257C (de) 1976-09-08
NO134257B (de) 1976-05-31
DD95007A5 (de) 1973-01-12

Similar Documents

Publication Publication Date Title
NL174943C (nl) Werkwijze ter bereiding van farmaceutische preparaten en werkwijze ter bereiding van een 8-azapurin-6-onderivaat.
NL173954C (nl) Werkwijze voor het bereiden van 4-amidopiperidineverbindingen en werkwijze voor het bereiden van farmaceutische preparaten.
NL176856C (nl) Werkwijze ter bereiding van nonapeptide-amiden, alsmede werkwijze ter bereiding van farmaceutische preparaten die deze nonapeptide-amiden bevatten, en gevormde farmaceutische preparaten.
NL150680B (nl) Werkwijze ter bereiding van farmaceutische preparaten.
NL174143C (nl) Werkwijze ter bereiding van floroglucinolverbindingen met vasodilatatieve werking, alsmede werkwijze ter bereiding van farmaceutische preparaten met een dergelijke werking.
NL174547C (nl) Werkwijze ter bereiding van benzoylpropionzuurderivaten, werkwijze ter bereiding van farmaceutische preparaten en gevormde farmaceutische preparaten.
NL144486B (nl) Werkwijze ter bereiding van farmaceutische en veterinaire preparaten.
NL172826C (nl) Werkwijze voor de bereiding van preparaten met hormonale werkingen.
NL173953C (nl) Werkwijze ter bereiding van herbicide preparaten.
NL170284C (nl) Werkwijze ter bereiding van 1.2.3.5.6.12.13.13a-octahydro 12 oxoindolo Ÿ3.2.1-d.eŸpyrido Ÿ3.2.1-i.jŸnaftyridinen, alsmede werkwijze ter bereiding van farmaceutische preparaten.
NL172240C (nl) Werkwijze om pteridinederivaten te bereiden en farmaceutische preparaten, welke deze verbindingen bevatten.
NL171702C (nl) Werkwijze ter bereiding van farmaceutische preparaten alsmede werkwijze ter bereiding van een beta-adrenolytisch werkzaam 1-(2-cyaanfenoxy)-2-hydroxy-3-alkylaminopropaan.
NL174830C (nl) Werkwijze ter bereiding van een purinenucleoside van beta-d-arabinofuranose en werkwijze ter bereiding van farmaceutische preparaten op basis van deze verbinding.
NL172657C (nl) Werkwijze ter bereiding van een farmaceutisch preparaat en werkwijze ter bereiding van daarbij bruikbare pyrazoloÿ3.4-bÿ-pyridine-derivaten.
NL174798C (nl) Werkwijze ter bereiding van acaricide preparaten.
NL173167C (nl) Werkwijze ter bereiding van farmaceutische preparaten, op basis van n-acyltryptofaanderivaten, alsmede werkwijze ter bereiding van n-acyltryptofaanderivaten.
NL163097C (nl) Werkwijze ter bereiding van gestabiliseerde preparaten.
NL142949B (nl) Werkwijze ter bereiding van salicylaatderivaten, werkwijze ter bereiding van farmaceutische preparaten, alsmede aldus verkregen gevormde preparaten.
NL165655C (nl) Werkwijze ter bereiding van een farmaceutisch preparaat, alsmede werkwijze ter bereiding van daarvoor geschikte peptiden.
NL174248C (nl) Werkwijze ter bereiding van farmaceutische preparaten; werkwijze voor het ontsmetten van apparatuur en werkwijze ter bereiding van een 3-fluoralanine.
NL170088C (nl) Werkwijze ter bereiding van herbicide preparaten.
NL176266C (nl) Werkwijze ter bereiding van cefalosporineesters en farmaceutische preparaten daaruit.
NL142670B (nl) Werkwijze ter bereiding van 19-norsteroiden, werkwijze ter bereiding van farmaceutische preparaten en gevormde farmaceutische preparaten.
NL172954C (nl) Werkwijze ter bereiding van triazolobenzodiazepinederivaten en werkwijze ter bereiding van farmaceutische preparaten.
NL176455C (nl) Werkwijze voor de bereiding van een alfa-dithiol.

Legal Events

Date Code Title Description
V1 Lapsed because of non-payment of the annual fee